How a Tech Entrepreneur Used AI to Create an Experimental Cancer Vaccine for His Dog

A tech entrepreneur in Australia has stunned scientists after using artificial intelligence to help create an experimental cancer vaccine for his dog — a story that highlights both the emotional power of human–animal bonds and the growing role of AI in scientific discovery.

When Sydney-based data engineer Paul Conyngham learned that his rescue dog Rosie had an aggressive form of mast cell cancer, the outlook was grim. Surgery and chemotherapy slowed the disease but failed to eliminate the tumours. Faced with limited options, Conyngham turned to ChatGPT to help explore potential treatments. What followed was an unusual collaboration between a determined dog owner, artificial intelligence tools and some of Australia’s leading biomedical researchers.

Using guidance from AI, Conyngham arranged for Rosie’s tumour and healthy DNA to be sequenced at the University of New South Wales. By comparing the two genetic datasets, he searched for mutations responsible for the cancer. Drawing on his background in machine learning, he then analysed the data using computational pipelines and consulted AI systems to interpret the results and identify possible therapeutic targets. He also used AlphaFold, a protein-structure prediction tool developed by DeepMind, to understand how the mutations affected proteins involved in the disease.

The effort caught the attention of researchers at the university’s Ramaciotti Centre for GenomicsDealroom has a profile for this one. Try Dealroom →, including computational biologist Martin Smith, who was initially surprised by the request. But as Conyngham continued analysing the data and presenting results, scientists became intrigued by the possibility of turning his findings into a treatment. The project soon expanded to include Pall Thordarson at the UNSW RNA Institute, who helped design a personalised mRNA cancer vaccine tailored to Rosie’s tumour mutations.

Messenger RNA, or mRNA, is a molecule that instructs cells to produce specific proteins. The technology gained global attention during the pandemic through vaccines for COVID-19, and researchers are increasingly studying it as a tool for cancer immunotherapy. In Rosie’s case, the custom-designed vaccine was intended to help her immune system recognise and attack cancer cells carrying the identified mutations.

After navigating ethical approvals, the experimental treatment was administered under the supervision of veterinary immunotherapy researcher Rachel Allavena at the University of Queensland. Rosie received her first injection in December, followed by booster doses in the following months. According to the research team, at least one large tumour shrank significantly, improving the dog’s comfort and energy levels.

Scientists caution that the results are preliminary and not proof of a cure. Still, the case has drawn attention for what it represents: a striking example of “citizen science,” where individuals use modern computational tools to participate in complex research. For cancer researchers, the project also hints at a future in which personalised mRNA therapies — designed from a patient’s genetic data — could be created more quickly and precisely.

For Conyngham, however, the motivation was simpler. Rosie, a staffy–shar pei mix he adopted from a shelter in 2019, had been a constant companion through difficult years. The experimental treatment cost tens of thousands of dollars and months of work, but he says he would do it again without hesitation. While he knows the vaccine may not be a permanent cure, he believes it has given his dog something invaluable: more time and a better quality of life.

Source:
The Economic Times
The Australian
The Times of India
Dawn

Image Credits:
John Feder

A.M.